1 / 6

UKPDS 38: study design

UKPDS 38: study design. Newly diagnosed hypertensive patients with type 2 diabetes (n = 1544). Previous antihypertensive treatment BP ≥ 150/85 mm Hg (n = 421). No previous antihypertensive treatment BP ≥ 160/90 mm Hg (n = 727). Randomisation. Less tight BP control (n = 390).

star
Télécharger la présentation

UKPDS 38: study design

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. UKPDS 38: study design Newly diagnosed hypertensive patients with type 2 diabetes (n = 1544) Previous antihypertensive treatment BP ≥ 150/85 mm Hg (n = 421) No previous antihypertensive treatment BP ≥ 160/90 mm Hg (n = 727) Randomisation Less tight BP control (n = 390) Tight BP control (n = 758) ACE inhibitor to maximum dose (n = 400) Beta-blocker to maximum dose(n = 358) Avoid ACE inhibitors/ beta-blockers (n = 390) UKPDS 38: BMJ 1998;317:703–13

  2. UKPDS 38: participant characteristics UKPDS 38: BMJ 1998;317:703–13

  3. Systolic BP Diastolic BP 165 96 Tight 94 Less tight 160 92 90 155 88 86 150 84 145 82 80 140 78 0 0 Baseline 9 years Baseline 9 years UKPDS 38: tight control had a greater effect on blood pressure Blood pressure (mm Hg) UKPDS 38: BMJ 1998;317:703–13

  4. UKPDS 38: relative risk reduction with tight blood pressure control Peripheral vascular disease Microvascular endpoint Any diabetes endpoint All-cause mortality Diabetes death MI Stroke Relative risk reduction tight vs less tight BP control(%) * p < 0.05 ** p < 0.01 ** * ** * UKPDS 38: BMJ 1998;317:703–13

  5. 160 60 Captopril Systolic Atenolol 50 140 Captopril 40 Atenolol 120 30 Absolute risk(events/1000 patients years) Blood pressure (mm Hg) 20 100 Diastolic 10 80 0 0 PVD 0 1 2 3 4 5 6 7 8 9 MI Stroke Years from randomisation Microvascular Diabetes death UKPDS 39: similar effects of beta-blocker and ACE inhibitor Any diabetes endpoint Adapted from: BMJ 1998;317:713–20

  6. 20 Captopril 18 Atenolol 16 14 12 10 8 6 4 2 0 GI Cough Headache Increasedcreatinine Impotence Depression Intermittent claudication Bronchospasm Allergic reaction Dizzy, tired, unwell UKPDS 39: reasons for non-compliance non-compliant patients (%) UKPDS 39: BMJ 1998;317:713–20

More Related